Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20141556 | 1.00 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL20129705 | 0.77 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL20141130 | 0.76 | CHRM2 (0.36) | — | |
| SCHEMBL20141457 | 0.76 | CYP2D6 (0.36) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL20141013 | 0.76 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL20129706 | 0.76 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL20133585 | 0.74 | PLD1 (0.41) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL30790940 | 0.72 | HTT (0.32) | — | |
| SCHEMBL30132155 | 0.71 | CYP2D6 (0.35) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL31484614 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3538091-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | Navitor Pharmaceuticals, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089499-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844013-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | SLC6A2 3251/4885SLC6A4 1595/4885SLC6A3 2743/4885 |
| US-10414727-B2 | Phenyl amino piperidine mTORC inhibitors and uses thereof | MTOR, RICTOR, RPTOR | SLC6A2 3251/4885SLC6A4 1595/4885SLC6A3 2743/4885 |
| US-20180127370-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | SLC6A2 3251/4885SLC6A4 1595/4885SLC6A3 2743/4885 |
| US-20200207716-A1 | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | SLC6A2 3251/4885SLC6A4 1595/4885SLC6A3 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.